Johnson & Johnson (NYSE:JNJ) Releases FY 2019 Earnings Guidance

Johnson & Johnson (NYSE:JNJ) issued an update on its FY 2019 earnings guidance on Tuesday morning. The company provided earnings per share guidance of $8.53-8.63 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $8.60. The company issued revenue guidance of $80.8-81.6 billion, compared to the consensus revenue estimate of $81.22 billion.Johnson & Johnson also updated its FY19 guidance to $8.53-8.63 EPS.

Shares of NYSE JNJ opened at $132.07 on Friday. Johnson & Johnson has a fifty-two week low of $121.00 and a fifty-two week high of $148.99. The firm’s 50 day simple moving average is $138.36. The company has a market capitalization of $350.10 billion, a P/E ratio of 16.15, a price-to-earnings-growth ratio of 2.28 and a beta of 0.70. The company has a quick ratio of 1.13, a current ratio of 1.44 and a debt-to-equity ratio of 0.47.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, July 16th. The company reported $2.58 EPS for the quarter, topping the consensus estimate of $2.42 by $0.16. Johnson & Johnson had a net margin of 20.08% and a return on equity of 38.57%. The firm had revenue of $20.56 billion during the quarter, compared to analyst estimates of $20.39 billion. During the same quarter in the previous year, the business posted $2.10 EPS. Johnson & Johnson’s revenue was down 1.3% on a year-over-year basis. As a group, research analysts forecast that Johnson & Johnson will post 8.59 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th will be paid a $0.95 dividend. This represents a $3.80 annualized dividend and a dividend yield of 2.88%. The ex-dividend date is Monday, August 26th. Johnson & Johnson’s payout ratio is 46.45%.

A number of research analysts have issued reports on JNJ shares. Zacks Investment Research lowered shares of Hallmark Financial Services from a buy rating to a hold rating in a report on Thursday. Raymond James reaffirmed a reduce rating and issued a $48.00 target price (up from $45.00) on shares of Hancock Whitney in a research report on Wednesday. Goldman Sachs Group set a $27.00 price target on Melco Resorts & Entertainment and gave the company a buy rating in a report on Tuesday, May 28th. Morgan Stanley set a $60.00 price target on Berry Global Group and gave the stock a hold rating in a research note on Wednesday, April 17th. Finally, Credit Suisse Group reissued a buy rating and issued a $90.00 price objective on shares of Bayerische Motoren Werke in a research note on Thursday. Five research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company presently has a consensus rating of Buy and an average target price of $148.56.

In other Johnson & Johnson news, Director Marillyn A. Hewson bought 3,000 shares of Johnson & Johnson stock in a transaction dated Tuesday, June 11th. The stock was acquired at an average cost of $139.68 per share, for a total transaction of $419,040.00. Following the completion of the transaction, the director now directly owns 3,000 shares of the company’s stock, valued at $419,040. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.23% of the stock is owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Article: Understanding each part of a balance sheet

Earnings History and Estimates for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit